Introduction
Background
The traditional term of unstable angina was first used 3 decades ago and was meant to signify the intermediate state between myocardial infarction (MI) and the more chronic state of stable angina. The old term, preinfarction angina, conveys the clinical intent of intervening to attenuate the risk of myocardial infarction or death. Patients with this condition have also been categorized according to their presentation, diagnostic test results, or course over time; these categories include new-onset angina, accelerating angina, rest angina, early postinfarct angina, and early postrevascularization angina.
For the pragmatic purposes of this article, the term unstable angina includes non–Q-wave myocardial infarction (NQMI) because this cannot be confirmed or excluded during the initial contact with the patient. Acute coronary syndromes cover an even wider spectrum, and by some definitions include Q-wave or transmural myocardial infarction.
Pathophysiology
Chest pain is a nonspecific symptom that can have cardiac or noncardiac causes (see Differentials). The term angina is typically reserved for pain syndromes arising from presumed myocardial ischemia.
Unstable angina belongs to the continuum of the acute coronary syndromes because of the shared pathophysiology, evaluation, and treatments with NQMI and Q-wave myocardial infarction. Although the etiology and definition of unstable angina can be broad, an interplay between disrupted atherosclerotic plaque and overlaid thrombi is present in many cases of unstable angina, with consequent hemodynamic deficit or microembolization. This is distinct from stable angina, in which the typical underlying cause is a fixed coronary stenosis with compromised blood flow and slow, progressive plaque growth that allows for the occasional development of collateral flow.
Other causes of angina, such as hypertrophic obstructive cardiomyopathy (HOCM) or microvascular disease (syndrome X), cause ischemia by means of different mechanisms and are considered separate entities.
Factors involved in the pathophysiology of unstable angina include supply-demand mismatch, plaque disruption or rupture, thrombosis, vasoconstriction, and cyclical flow.
Supply-demand mismatchThe myocardial ischemia of unstable angina, like all tissue ischemia, results from excessive demand or inadequate supply of oxygen, glucose, and free fatty acids.
Secondary disorders cause ischemia by increasing myocardial oxygen demand (eg, thyrotoxicosis, cocaine, severe illness, physiologic stress) or by decreasing oxygen supply (eg, hypoxemia, anemia, hypotension). Such causes must be investigated because most of these conditions are reversible. For instance, anemia from chronic gastrointestinal bleeding is not uncommon in elderly patients. This can coexist with coronary artery disease (CAD). However, patients may not benefit or may be harmed by treatments such as anticoagulants and antiplatelet drugs. Avoidance or treatment of the underlying condition is paramount.
Excess demand from increased myocardial workload (heart rate–systolic pressure product) or wall stress is responsible for nearly all cases of stable angina and perhaps one third of all episodes of unstable angina.
Plaque disruption
Accumulation of lipid-laden macrophages and smooth muscle cells, so-called foam cells, occurs within atherosclerotic plaques. The oxidized low-density lipoprotein cholesterol (LDL-C) in foam cells is cytotoxic, procoagulant, and chemotactic. As the atherosclerotic plaque grows, production of macrophage proteases and neutrophil elastases within the plaque can cause thinning of the fibromuscular cap that covers the lipid core. Increasing plaque instability coupled with blood-flow shear and circumferential wall stress lead to plaque fissuring or rupture, especially at the junction of the cap and the vessel wall.
The pathogenesis of acute coronary syndrome is shown in the image below.
Pathogenesis of acute coronary syndromes.
The degree and consequence of plaque disruption covers a wide spectrum. Minor fissuring is typically nonocclusive and hence clinically silent, and repeat occult episodes of plaque ulceration and healing with a gradual growth of plaque volume have been histologically documented. Moderate-to-large plaque disruptions commonly result in unstable angina or acute infarction.
Thrombosis
Exposure of subendothelial components provokes platelet adhesion and activation. Platelets then aggregate in response to exposed vessel wall collagen or local aggregates (eg, thromboxane, adenosine diphosphate). Platelets also release substances that promote vasoconstriction and production of thrombin. In a reciprocating fashion, thrombin is a potent agonist for further platelet activation, and it stabilizes thrombi by converting fibrinogen to fibrin.
The nonocclusive thrombus of unstable angina can become transiently or persistently occlusive. Depending on the duration of occlusion, the presence of collateral vessels, and the area of myocardium perfused, recurrent unstable angina, NQMI, or Q-wave infarction can result.
Vasoconstriction, vasospasm, and cyclic flow variation
Most patients with acute coronary syndrome have recurrent transient reduction in coronary blood supply because of vasoconstriction and thrombus formation at the site of atherosclerotic plaque rupture. These events occur because of episodic platelet aggregation and complex interactions among the vascular wall, leukocytes, platelets, and atherogenic lipoproteins.
Vasospasm, provoked by either ergonovine or acetylcholine, is a common finding in patients with acute coronary syndrome, particularly in Taiwanese and Japanese patients. Although correlated with chest pain, whether this coronary hyperreactivity causes acute coronary syndrome or is simply an associated finding is not known.1
Frequency
United States
The incidence of unstable angina is increasing, and nearly 1 million hospitalized patients each year have a primary diagnosis of unstable angina.
A similar number of unstable angina episodes likely occur outside the hospital and are unrecognized or managed in the outpatient setting. With heightened public awareness, improved survival after myocardial infarction, and aging of the population, this number should continue to rise despite primary and secondary prevention measures.
Reasonably representative statistical estimates for unstable angina can be obtained from 2 registries, the Global Unstable Angina Registry and Treatment Evaluation (GUARANTEE) registry2,3 or the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA (CRUSADE) registry.4 GUARANTEE involved 3000 consecutive hospital admissions for unstable angina in 35 hospitals in 6 geographic regions (Northeast, Mideast, Midwest, Southeast, Southwest, Northwest) from September 1995 to August 1996. CRUSADE registered more than 180,000 patients with non–ST-segment elevation myocardial infarction (NSTEMI) in the US from 2001-2006, targeting high-risk patients with unstable angina or NSTEMI using the following inclusion criteria: (1) chest pain or anginal equivalent at rest, more than 10 minutes in duration; (2) ischemic ECG changes (ST-segment depression >0.5 mm, transient ST-segment elevation 0.5–1.0 mm lasting for<10min);and/or (3) elevated markers of myocardial necrosis (CK-MB and/or troponin I or T > the upper limit of normal for the local laboratory assay used at each institution).The demographics and characteristics of patients in the GUARANTEE registry compared with the CRUSADE registry are shown in Table 1.
Table 1. Patient Characteristics, GUARANTEE Versus CRUSADE
Open table in new window
Table
| | GUARANTEE, 1995-96 | CRUSADE, 2001-06 |
| Mean age | 62 y | 69 y |
| Patients older than 65 y | 44% | |
| Female | 39% | 40% |
| Hypertension | 60% | 73% |
| Diabetes mellitus | 26% | 33% |
| Current smoker | 25% | |
| Hypercholesterolemia | 43% | 50% |
| Previous stroke | 9% | |
| Previous myocardial infarction | 36% | 30% |
| Previous angina | 66% | |
| Congestive heart failure | 14% | 18% |
| Previous coronary intervention | 23% | 21% |
| Previous coronary bypass surgery | 25% | 19% |
| | GUARANTEE, 1995-96 | CRUSADE, 2001-06 |
| Mean age | 62 y | 69 y |
| Patients older than 65 y | 44% | |
| Female | 39% | 40% |
| Hypertension | 60% | 73% |
| Diabetes mellitus | 26% | 33% |
| Current smoker | 25% | |
| Hypercholesterolemia | 43% | 50% |
| Previous stroke | 9% | |
| Previous myocardial infarction | 36% | 30% |
| Previous angina | 66% | |
| Congestive heart failure | 14% | 18% |
| Previous coronary intervention | 23% | 21% |
| Previous coronary bypass surgery | 25% | 19% |
International
The best demographic data available are from the Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) registry. It included 7987 patients with acute myocardial ischemia without ST elevation from 95 hospitals across 6 countries. Table 2 lists the patients' characteristics.
Table 2. Demographic Characteristics of Patients in the International OASIS-2 Registry
Open table in new window
Table
| Characteristics | Australia | Brazil | Canada | Hungary | Poland | United States | |
| General | Number of patients | 1899 | 1478 | 1626 | 931 | 1135 | 918 |
| Mean age (y) | 65 | 62 | 66 | 65 | 63 | 66 | |
| Women (%) | 37 | 42 | 37 | 45 | 40 | 37 | |
| Clinical | NQMI presentation (%) | 7 | 7 | 14 | 22 | 17 | 16 |
| Abnormal ECG (%) | 74 | 91 | 82 | 95 | 97 | 87 | |
| Select treatments | Beta-blocker (%) | 67 | 53 | 73 | 67 | 59 | 57 |
| Calcium blocker (%) | 59 | 51 | 53 | 52 | 43 | 59 | |
| Invasive procedures (index hospitalization) | Cardiac catheterization (%) | 24 | 69 | 43 | 20 | 7 | 58 |
| Percutaneous coronary intervention (PCI) (%) | 7 | 19 | 16 | 5 | 0.4 | 24 | |
| Coronary artery bypass graft (CABG) (%) | 4 | 20 | 10 | 7 | 0.4 | 17 | |
| Characteristics | Australia | Brazil | Canada | Hungary | Poland | United States | |
| General | Number of patients | 1899 | 1478 | 1626 | 931 | 1135 | 918 |
| Mean age (y) | 65 | 62 | 66 | 65 | 63 | 66 | |
| Women (%) | 37 | 42 | 37 | 45 | 40 | 37 | |
| Clinical | NQMI presentation (%) | 7 | 7 | 14 | 22 | 17 | 16 |
| Abnormal ECG (%) | 74 | 91 | 82 | 95 | 97 | 87 | |
| Select treatments | Beta-blocker (%) | 67 | 53 | 73 | 67 | 59 | 57 |
| Calcium blocker (%) | 59 | 51 | 53 | 52 | 43 | 59 | |
| Invasive procedures (index hospitalization) | Cardiac catheterization (%) | 24 | 69 | 43 | 20 | 7 | 58 |
| Percutaneous coronary intervention (PCI) (%) | 7 | 19 | 16 | 5 | 0.4 | 24 | |
| Coronary artery bypass graft (CABG) (%) | 4 | 20 | 10 | 7 | 0.4 | 17 | |
Because unstable angina is intimately linked to the incidence of coronary events, an approximation of international trends might be found in the Monitoring Trends and Determinants in Cardiovascular Diseases (MONICA) Registry sponsored by the World Health Organization (WHO). This large project monitored more than 7 million people aged 35-64 years from 30 populations in 21 countries from the mid 1980s. The highest average rates of heart disease were found in Glasgow and Belfast, United Kingdom; North Karelia and Kuopio, Finland; Newcastle, Australia; and Warsaw, Poland. The lowest average myocardial infarction rates, and presumably unstable angina rates, were observed in Beijing, China; Toulouse, France; Catalonia, Spain; Vaud-Fribourg, Switzerland; and Brianza, Italy.5
Mortality/Morbidity
The risk of death, myocardial infarction, and complications is variable because of the broad clinical spectrum that is covered by the term unstable angina. The average risk for these patients is discussed here. More specific risk stratification is detailed in Treatment. The aggressiveness of the therapeutic approach should be commensurate to the individualized estimated risk.
Older studies show that the incidence of death in the early weeks after hospitalization is approximately 4%, and the incidence of myocardial infarction is approximately 10%.
Thirty-day event rates are the current standard for cross-comparing studies. The aggregate data for the more than 40,000 patients with acute coronary syndromes in studies using contemporary treatments (albeit in varying degrees) indicate improving outcomes (see Table 3). The 30-day death and myocardial infarction rates are currently around 3.5% and 8.5%, respectively, in spite of increased disease complexity and an aging cohort.
Table 3. Thirty-Day Clinical Outcome in Patients With Acute Coronary Syndromes in Clinical Trials
Open table in new window
Table
| Study | Year | Number of Patients | Death (%) | MI (%) | Major Bleed (%) |
| TIMI-3* | 1994 | 1,473 | 2.5 | 9.0 | 0.3 |
| GUSTO-IIb† | 1997 | 8,011 | 3.8 | 6.0 | 1.0 |
| ESSENCE‡ | 1998 | 3,171 | 3.3 | 4.5 | 1.1 |
| PARAGON-A§ | 1998 | 2,282 | 3.2 | 10.3 | 4.0 |
| PRISM|| | 1998 | 3,232 | 3.0 | 4.2 | 0.4 |
| PRISM-PLUS¶ | 1998 | 1,915 | 4.4 | 8.1 | 1.1 |
| PURSUIT# | 1998 | 10,948 | 3.6 | 12.9 | 2.1 |
| TIMI-11B** | 1999 | 3,910 | 3.9 | 6.0 | 1.3 |
| PARAGON-B†† | 2000 | 5,225 | 3.1 | 9.3 | 1.1 |
| Pooled | 40,167 | 3.5 | 8.5 | 1.5 | |
| Study | Year | Number of Patients | Death (%) | MI (%) | Major Bleed (%) |
| TIMI-3* | 1994 | 1,473 | 2.5 | 9.0 | 0.3 |
| GUSTO-IIb† | 1997 | 8,011 | 3.8 | 6.0 | 1.0 |
| ESSENCE‡ | 1998 | 3,171 | 3.3 | 4.5 | 1.1 |
| PARAGON-A§ | 1998 | 2,282 | 3.2 | 10.3 | 4.0 |
| PRISM|| | 1998 | 3,232 | 3.0 | 4.2 | 0.4 |
| PRISM-PLUS¶ | 1998 | 1,915 | 4.4 | 8.1 | 1.1 |
| PURSUIT# | 1998 | 10,948 | 3.6 | 12.9 | 2.1 |
| TIMI-11B** | 1999 | 3,910 | 3.9 | 6.0 | 1.3 |
| PARAGON-B†† | 2000 | 5,225 | 3.1 | 9.3 | 1.1 |
| Pooled | 40,167 | 3.5 | 8.5 | 1.5 | |
* TIMI-3: Thrombolysis in Myocardial Infarction Clinical Trial 3 † GUSTO-IIb: Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries
‡ ESSENCE: Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-wave Coronary Events
§ PARAGON-A: Platelet IIb/IIIa Antagonism (lamifiban) for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network
|| PRISM: Platelet Receptor Inhibition in Ischemic Syndrome Management
¶ PRISM-PLUS: Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Angina Signs and Symptoms
# PURSUIT: Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
** TIMI-11B: Thrombolysis in Myocardial Infarction Clinical Trial 11B
†† PARAGON-B: Platelet IIb/IIIa Antagonism (lamifiban) for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network
The Recursos Empleados en el Sindrome Coronario Agudo y Tiempos de Espera (RESCATE) investigators from Spain report a 1.8% mortality rate and a 5.1% myocardial infarction rate at 28 days (n = 791, consecutive series between 1992 and 1994, early revascularization rate about 6%).7 By comparison with the therapeutically aggressive and predominantly North American studies listed in Table 2, these adverse event rates seem lower, probably because of the healthier case-mix (patients with unstable angina without previous myocardial infarction), which illustrates the difficulties of direct outcome comparisons between institutions and countries and across different trials.
The outcome in patients with abnormal electrocardiographic findings, and in particular ST-segment depression, approximates that of patients with acute myocardial infarction. Other predictors of worse long-term outcome in unstable angina include advanced age, underlying left ventricular systolic dysfunction, and more widespread extent of coronary artery disease.
Race
Disparities in outcomes and the prevalence of risk factors among different ethnic groups have been widely reported. For instance, as a group, blacks exhibit a higher prevalence of atherosclerotic risk factors (eg, hypertension, diabetes mellitus, smoking), greater left ventricular mass, and decreased peripheral vasodilatory response. Relative to whites, myocardial infarction more frequently results in death in blacks at young ages.
- Fewer myocardial events but more cerebral complications have been observed in black patients with unstable angina in randomized clinical trials of heparin versus hirudin (GUSTO II) or eptifibatide versus placebo (PURSUIT). This may be due to the enhanced fibrinolytic activity and higher prevalence of hypertension in this population.
- Differences also exist in the delivery and response to medical care. Whites have a higher rate of catheterization, angioplasty, and bypass surgery than other racial groups. An analysis of Medicare beneficiaries also showed underuse of catheterization, particularly for managed-care enrollees as opposed to fee-for-service beneficiaries. The coronary angiography rates even for those with American College of Cardiology/American Heart Association (ACC/AHA) class I indications (angiography deemed useful or effective) in this post-myocardial infarction study were 46% versus 37%, respectively (P < .001).
- Studies have shown equivalent short-term (30-day) mortality rates from unstable angina (including NQMI) for blacks, but over the long term, persistent worse outcomes have been demonstrated.
Sex
Women with unstable angina are older and have a higher prevalence of hypertension, diabetes mellitus, congestive heart failure, and family history of coronary artery disease than men. Men tend to have a higher previous incidence of myocardial infarction and revascularization, a higher proportion of positive cardiac enzymes on admission, and higher rates of catheterization and revascularization. However, outcome is related more to the severity of the illness than to sex.
Age
The mean age of presentation with unstable angina is 62 years, with an age range of 23-100 years. To put this in perspective, the mean age is 60 years for patients in clinical trials for myocardial infarction, about 67 years for carotid artery stenosis, and 63 years for congestive heart failure. On average, women with unstable angina are 5 years older than men on presentation, with approximately half of women older than 65 years, as opposed to only about a third of men. Blacks tend to present at a slightly younger age (mean ± standard deviation, 59 ± 13 y) than people of other races.
Clinical
History
Patients with unstable angina represent a heterogeneous population. Therefore, the clinician must obtain a focused history of the patient's symptoms and coronary risk factors and immediately review the ECG to develop an early risk stratification.
- Initially obtain history to determine whether any evidence of angina is present, and then aim to identify whether it is stable or unstable.
- Unstable angina differs from stable angina in that the discomfort is usually more intense and easily provoked, and ST-segment depression or elevation on ECG may occur. Otherwise, the manifestations of unstable angina are similar to those of other conditions of myocardial ischemia such as chronic stable angina and myocardial infarction.
- Angina can take many forms, and inquiry should be directed at eliciting not only chest pain but also any discomfort and its frequency, location, radiation pattern, and precipitating and alleviating factors. Ischemic pain can manifest as heaviness, tightness, aching, fullness, or burning of the chest, epigastrium, and/or arm or forearm (usually the left). These sensations less typically involve the lower jaw, neck, or shoulder. Important associated symptoms may be dyspnea, generalized fatigue, diaphoresis, nausea and vomiting, flu-like symptoms, and, less commonly, lightheadedness or abdominal pain.
- Elderly and female patients are more likely to present with atypical signs and symptoms.
Risk assessment (Diagnosis)
Clinical tip: Simply put, the 2 fundamental questions in the approach to the patient with possible angina are the following: (1) Is this coronary artery disease? (That is, what is the diagnosis, or what does the patient have?) (2) How dangerous is this? (That is, what is the prognosis, or what is the risk of something bad happening next?) Therefore, a brief history and physical examination, resting 12-lead ECG, and blood draw for evaluation of cardiac enzymes should be accomplished expeditiously.
Estimation of likelihood of acute coronary syndrome is a complex multivariable problem that cannot be fully specified in a list such as this. The following is meant to illustrate major relationships rather than offer rigid algorithms. The likelihood of significant coronary artery disease in patients presenting with chest pain syndrome is as follows:
- High likelihood (includes any of the following features):
- History of prior myocardial infarction, sudden death, or other known history of coronary artery disease
- Chest or left arm pain consistent with prior documented angina
- Transient hemodynamic or ECG changes during pain
- ST-segment elevation or depression 1 mm or more
- Marked symmetrical T-wave inversion in multiple precordial leads
- Intermediate likelihood (includes absence of high likelihood features, but one of these risk characteristics is present):
- Age older than 70 years
- Male sex
- Diabetes mellitus
- Extracardiac vascular disease (peripheral, brachiocephalic, or renal artery atherosclerosis)
- ST depression 0.05-1 mm
- T-wave inversion 1 mm or greater in leads with dominant R waves
- Low likelihood (includes absence of high or intermediate likelihood features and any of the following):
- Chest pain classified as probably not angina
- Chest discomfort reproduced by palpation
- T-wave flattening or inversion less than 1 mm in leads with dominant R waves
- Normal ECG findings
Risk stratification (Prognosis)
After the likelihood for coronary artery disease is determined to be significant, the next step is to stratify the patient's risk for an event. The estimation of likelihood of significant coronary artery disease is critical for identifying high-risk patients who may benefit from more aggressive treatment strategy (ie, cardiac catheterization).
The TIMI Risk Score for unstable angina/NSTEMI is currently the best-validated prognostic instrument that is simple enough to use in an emergency department setting. The gradient of death, myocardial infarction, or severe recurrent ischemia is somewhat proportionate to the TIMI Risk Score.
Thrombolysis in Myocardial Infarction (TIMI) Risk Score correlates with major adverse outcome and the effect of therapy with low molecular weight heparin.
The presence of any of the following variables constitutes 1 point, with the sum constituting the patient risk score on a scale of 0-7:
- Aged 65 years or older
- Use of aspirin in the last 7 days
- Known coronary stenosis of 50% or greater
- Elevated serum cardiac markers
- At least 3 risk factors for coronary artery disease (including diabetes mellitus, active smoker, family history of coronary artery disease, hypertension, hypercholesterolemia)
- Severe anginal symptoms (2 or more anginal events in the last 24 h)
- ST deviation on ECG
Of note, studies have shown that ongoing congestive heart failure, presence/history of poor left ventricular ejection fraction (LVEF), hemodynamic instability, recurrent angina despite intensive anti-ischemic therapy, new or worsening mitral regurgitation, or sustained ventricular tachycardia are significant prognosticators for poor outcome. However, these factors were not evaluated in the TIMI Risk Score model and should be taken into consideration when the level of care is decided.
Factors that were specifically examined but were not found to have prognostic value in the multivariate model include prior myocardial infarction, previous percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft, or history of congestive heart failure.
The inflection point for death or myocardial infarction starts at a TIMI Risk Score of 3. Therefore, patients with a score of 3-7 should be considered for use of intravenous glycoprotein IIb/IIIa agents, heparin (low molecular weight or unfractionated), and early cardiac catheterization (see Treatment).
Classification of unstable angina
The number and diversity of clinical conditions that cause the transient myocardial ischemia of unstable angina along with its varying intensity and frequency of pain have made classification within this disorder difficult.
The Braunwald classification is conceptually useful because it factors in the clinical presentation (new or progressive vs rest angina), context (primary, secondary, or post–myocardial infarction), and intensity of antianginal therapy.
[#targetD]Table 4. Braunwald Classification of Unstable Angina
Open table in new window
Table
| Characteristic | Class/Category | Details |
| Severity | I | Symptoms with exertion |
| II | Subacute symptoms at rest (2-30 d prior) | |
| III | Acute symptoms at rest (within prior 48 h) | |
| Clinical precipitating factor | A | Secondary |
| B | Primary | |
| C | Postinfarction | |
| Therapy during symptoms | 1 | No treatment |
| 2 | Usual angina therapy | |
| 3 | Maximal therapy |
| Characteristic | Class/Category | Details |
| Severity | I | Symptoms with exertion |
| II | Subacute symptoms at rest (2-30 d prior) | |
| III | Acute symptoms at rest (within prior 48 h) | |
| Clinical precipitating factor | A | Secondary |
| B | Primary | |
| C | Postinfarction | |
| Therapy during symptoms | 1 | No treatment |
| 2 | Usual angina therapy | |
| 3 | Maximal therapy |
Patients in class I have new or accelerated exertional angina, whereas those in class II have subacute (>48 h since last pain) or class III acute (<48 h since last pain) rest angina. The clinical circumstances associated with unstable angina are categorized as (A) secondary (anemia, fever, hypoxia), (B) primary, or (C) postinfarction (<2 wk after infarction). Intensity of antianginal therapy is subclassified as (1) no treatment, (2) usual oral therapy, and (3) intense therapy, such as intravenous nitroglycerin.
The Canadian Cardiovascular Society Grading System for effort-related angina is widely used since it is a simple and practical classification that is often used to describe symptom severity. It is as follows:
- Grade I: Angina with strenuous, rapid, or prolonged exertion. (Ordinary physical activity such as climbing stairs does not provoke angina.)
- Grade II: Slight limitation of ordinary activity. (Angina occurs with postprandial, uphill, or rapid walking; when walking more than 2 blocks of level ground or climbing more than one flight of stairs; during emotional stress; or in the early hours after awakening.)
- Grade III: Marked limitation of ordinary activity. (Angina occurs with walking 1-2 blocks or climbing a flight of stairs at a normal pace.)
- Grade IV: Inability to carry on any physical activity without discomfort. (Rest pain occurs.)
ECG evaluation
- The first line of assessment in any patient with suspected unstable angina is the 12-lead ECG, which should be obtained within 10 minutes of the patient's arrival to the emergency department. The diagnostic accuracy of an ECG is enhanced if a prior tracing is available for comparison.
- The highest-risk ECG findings (ST-segment elevation or new left bundle-branch block) necessitate immediate triage for revascularization therapy. Peaked T waves may also indicate early myocardial infarction.
- The next level of high-risk patients includes those with ST depression greater than 1 mm on ECG. Approximately 50% of patients with this finding have subendocardial myocardial necrosis. The presence of ST-segment depression portends relatively high in-hospital, 30-day, and 1-year mortality rates irrespective of cardiac biomarker level.
- New or reversible ST-segment deviation of 0.5 mm or more from baseline has been associated with a higher incidence (15.8% vs 8.2%) of 1-year death or myocardial infarction in the TIMI-III Registry ECG Ancillary study.
- Primary T wave changes are neither sensitive nor specific for ischemia, but they become an important clue in the context of symptoms or if the QRS to T-wave angle is greater than 60°. Isolated symmetric T-wave inversion does not appear to carry additional adverse prognosis.
- Clinical tip: The presence of ST-segment elevation or depression on ECG indicates high risk and must therefore be detected and acted on as soon as possible.
Physical
The physical examination is usually not as sensitive or specific for unstable angina as history or diagnostic tests. An unremarkable physical examination is not uncommon. Perform a quick assessment of patients' vital signs, and perform a cardiac examination. Specific diagnoses that must be explicitly considered are aortic dissection, leaking or ruptured thoracic aneurysm, pericarditis with tamponade, pulmonary embolism, and pneumothorax. Ideally, a 12-lead ECG should be performed within 10 minutes of presentation.
- Increased autonomic activity may manifest as diaphoresis or tachycardia, and bradycardia may result from vagal stimulation from inferior wall myocardial ischemia.
- A large area of myocardial jeopardy may manifest as signs of transient myocardial dysfunction and typically signifies a higher-risk situation.
- Systolic blood pressure less than 100 mm Hg or overt hypotension
- Elevated jugular venous pressure
- Dyskinetic apex
- Reverse splitting of the second heart sound
- Presence of a third or fourth heart sound
- New or worsening apical systolic murmur due to papillary muscle dysfunction
- Rales or crackles
- Findings indicative of peripheral arterial occlusive disease or prior stroke increases the likelihood of associated coronary artery disease.
- Carotid bruit
- Supraclavicular or femoral bruits
- Diminished peripheral pulses or blood pressure
- Clinical tip: Any sign of congestive heart failure, including isolated tachycardia, particularly in physiologically vulnerable populations (eg, very elderly patients), should trigger expeditious work-up, treatment, or consultation with a cardiologist. Such patients can deteriorate rapidly.
Causes
Many different conditions can provoke myocardial ischemia (Braunwald class A), including the following:
- Increased myocardial oxygen demand (See Supply-demand mismatch in Pathophysiology.)
- Fever
- Tachyarrhythmias (eg, atrial fibrillation or flutter)
- Malignant hypertension
- Thyrotoxicosis
- Pheochromocytoma
- Cocaine use
- Amphetamine use
- Aortic stenosis
- Supravalvular aortic stenosis
- Obstructive cardiomyopathy
- Aortovenous shunts
- High output states
- Congestive failure
- Decreased oxygen supply
- Anemia
- Hypoxemia
- Polycythemia
More on Unstable Angina |
 Overview: Unstable Angina |
| Differential Diagnoses & Workup: Unstable Angina |
| Treatment & Medication: Unstable Angina |
| Follow-up: Unstable Angina |
| Multimedia: Unstable Angina |
| References |
| Next Page » |
References
Ong P, Athanasiadis A, Hill S, Vogelsberg H, Voehringer M, Sechtem U. Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. J Am Coll Cardiol. Aug 12 2008;52(7):523-7. [Medline].
Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. Apr 4 2001;285(13):1711-8. [Medline].
Scirica BM, Moliterno DJ, Every NR, et al. Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. Am J Cardiol. Nov 15 1999;84(10):1145-50. [Medline].
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. Aug 16 2001;345(7):494-502. [Medline].
Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med. Jul 16 1992;327(3):141-5. [Medline].
GRACE, Global Registry of Acute Coronary Events. Available at http://www.outcomes- umassmed.org/grace/. Accessed March 30, 2009.
Lupón J, Valle V, Marrugat J, et al. Six-month outcome in unstable angina patients without previous myocardial infarction according to the use of tertiary cardiologic resources. RESCATE Investigators. Recursos Empleados en el Síndrome Coronario Agudo y Tiempos de Espera. J Am Coll Cardiol. Dec 1999;34(7):1947-53. [Medline].
Scanlon PJ, Nemickas R, Moran JF, Talano JV, Amirparviz F, Pifarre R. Accelerated angina pectoris. Clinical, hemodynamic, arteriographic, and therapeutic experience in 85 patients. Circulation. Jan 1973;47(1):19-26. [Medline].
Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol. Dec 1995;26(7):1643-50. [Medline].
Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med. Jun 18 1998;338(25):1785-92. [Medline].
FRISC Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet. Aug 28 1999;354(9180):708-15. [Medline].
Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. Aug 14 2007;116(7):e148-304. [Medline].
Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. Aug 14 2007;116(7):e148-304. [Medline].
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. Nov 16 1996;348(9038):1329-39. [Medline].
GUSTO Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med. Sep 12 1996;335(11):775-82. [Medline].
Akkerhuis KM, Deckers JW, Boersma E, et al. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. Eur Heart J. Mar 2000;21(5):371-81. [Medline].
Alexander JH, Sparapani RA, Mahaffey KW, et al. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. JAMA. Jan 19 2000;283(3):347-53. [Medline].
Ambrose JA, Winters SL, Stern A, et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol. Mar 1985;5(3):609-16. [Medline].
Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. Aug 16 2000;284(7):835-42. [Medline].
Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. Oct 31 1996;335(18):1342-9. [Medline].
Asher CR, Topol EJ, Moliterno DJ. Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes. Am Heart J. Dec 1999;138(6 Pt 1):1073-81. [Medline].
Balady GJ, Ades PA, Comoss P, et al. Core components of cardiac rehabilitation/secondary prevention programs: A statement for healthcare professionals from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation Writing Group. Circulation. Aug 29 2000;102(9):1069-73. [Medline].
Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation. Jul 1990;82(1):17-26. [Medline].
[Best Evidence] Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. Oct 3 2006;48(7):1319-25. [Medline].
Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med. Apr 1 1998;128(7):541-4. [Medline].
Bhatt DL, Houghtaling P, Harrington RA, et al. Black patients presenting with acute coronary syndromes have better outcomes due to less extent of disease. J Am Coll Cardiol. 1999;33(2):365A.
Bittner V, Weiner DH, Yusuf S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. JAMA. Oct 13 1993;270(14):1702-7. [Medline].
Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. Apr 12 2007;356(15):1503-16. [Medline].
Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. Apr 12 2007;356(15):1503-16. [Medline].
Braunwald E. Unstable angina. A classification. Circulation. Aug 1989;80(2):410-4. [Medline].
Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. Sep 2000;36(3):970-1062. [Medline].
Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation. Sep 5 2000;102(10):1193-209. [Medline].
Braunwald E, Mark DB, Jones RH, et al. Agency for Health Care and Policy Research (AHCPR). Unstable Angina. In: Diagnosis and Management. US Department of Health and Human Services. Washington, DC; 1994.
Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging in patients with unstable angina who respond to medical treatment. J Am Coll Cardiol. Apr 1991;17(5):1053-7. [Medline].
Butman SM, Olson HG, Butman LK. Early exercise testing after stabilization of unstable angina: correlation with coronary angiographic findings and subsequent cardiac events. Am Heart J. Jan 1986;111(1):11-8. [Medline].
Calvin JE, Klein LW, VandenBerg EJ, Meyer P, Parrillo JE. Validated risk stratification model accurately predicts low risk in patients with unstable angina. J Am Coll Cardiol. Nov 15 2000;36(6):1803-8. [Medline].
Campeau L. Letter: Grading of angina pectoris. Circulation. Sep 1976;54(3):522-3. [Medline].
Cannon CP, McCabe CH, Stone PH, et al. Prospective validation of the Braunwald classification of unstable angina: results from the Thrombolysis in Myocardial Ischemia (TIMI) III registry. Circulation. 1995;95(92):1-19.
Cannon CP, McCabe CH, Stone PH, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol. Jul 1997;30(1):133-40. [Medline].
Capone G, Wolf NM, Meyer B, Meister SG. Frequency of intracoronary filling defects by angiography in angina pectoris at rest. Am J Cardiol. Sep 1 1985;56(7):403-6. [Medline].
Chew DP, Moliterno DJ. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol. Dec 2000;36(7):2028-35. [Medline].
Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. Aug 14 1997;337(7):447-52. [Medline].
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. Jan 8 1994;308(6921):81-106. [Medline].
Das P, Moliterno DJ. Fractionating heparins and their clinical trial data--something for everyone. JAMA. Jul 7 2004;292(1):101-3. [Medline].
de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med. Sep 15 2005;353(11):1095-104. [Medline].
Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med. Jul 15 2004;117(2):73-81. [Medline].
EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med. Jun 12 1997;336(24):1689-96. [Medline].
EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. Jul 11 1998;352(9122):87-92. [Medline].
ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet. Dec 16 2000;356(9247):2037-44. [Medline].
Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. Apr 1985;71(4):699-708. [Medline].
Fowler NO. "Preinfarctional" angina. A need for an objective definition and for a controlled clinical trial of its management. Circulation. Nov 1971;44(5):755-8. [Medline].
Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet. Sep 10-16 2005;366(9489):914-20. [Medline].
Freeman MR, Chisholm RJ, Armstrong PW. Usefulness of exercise electrocardiography and thallium scintigraphy in unstable angina pectoris in predicting the extent and severity of coronary artery disease. Am J Cardiol. Dec 1 1988;62(17):1164-70. [Medline].
Freeman MR, Williams AE, Chisholm RJ, Armstrong PW. Intracoronary thrombus and complex morphology in unstable angina. Relation to timing of angiography and in-hospital cardiac events. Circulation. Jul 1989;80(1):17-23. [Medline].
Gasser JA, Betterridge DJ. Comparison of the effects of carvedilol, propranolol, and verapamil on in vitro platelet function in healthy volunteers. J Cardiovasc Pharmacol. 1991;18 Suppl 4:S29-34. [Medline].
Goldman L, Cook EF, Johnson PA, Brand DA, Rouan GW, Lee TH. Prediction of the need for intensive care in patients who come to the emergency departments with acute chest pain. N Engl J Med. Jun 6 1996;334(23):1498-504. [Medline].
Gotoh K, Minamino T, Katoh O, et al. The role of intracoronary thrombus in unstable angina: angiographic assessment and thrombolytic therapy during ongoing anginal attacks. Circulation. Mar 1988;77(3):526-34. [Medline].
Gottlieb SO, Weisfeldt ML, Ouyang P, Mellits ED, Gerstenblith G. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med. May 8 1986;314(19):1214-9. [Medline].
Guadagnoli E, Landrum MB, Peterson EA, Gahart MT, Ryan TJ, McNeil BJ. Appropriateness of coronary angiography after myocardial infarction among Medicare beneficiaries. Managed care versus fee for service. N Engl J Med. Nov 16 2000;343(20):1460-6. [Medline].
Harrington RA. Platelet IIb/IIIa in Unstable Angina:. Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. For the PURSUIT Investigators. 1998.
Heeschen C, Hamm CW, Goldmann B, Deu A, Langenbrink L, White HD. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet. Nov 20 1999;354(9192):1757-62. [Medline].
Hochman JS, McCabe CH, Stone PH, et al. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. Jul 1997;30(1):141-8. [Medline].
Hohnloser SH, Meinertz T, Klingenheben T, Sydow B, Just H. Usefulness of esmolol in unstable angina pectoris. European Esmolol Study Group. Am J Cardiol. Jun 15 1991;67(16):1319-23. [Medline].
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med. May 21 1998;338(21):1488-97. [Medline].
Kirk JD, Turnipseed S, Lewis WR, Amsterdam EA. Evaluation of chest pain in low-risk patients presenting to the emergency department: the role of immediate exercise testing. Ann Emerg Med. Jul 1998;32(1):1-7. [Medline].
Krone RJ, Greenberg H, Dwyer EM Jr, Kleiger RE, Boden WE. Long-term prognostic significance of ST segment depression during acute myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. J Am Coll Cardiol. Aug 1993;22(2):361-7. [Medline].
Lange RA, Cigarroa RG, Flores ED, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med. Jun 15 1990;112(12):897-903. [Medline].
Langer A, Freeman MR, Armstrong PW. ST segment shift in unstable angina: pathophysiology and association with coronary anatomy and hospital outcome. J Am Coll Cardiol. Jun 1989;13(7):1495-502. [Medline].
Larsson H, Areskog M, Areskog NH, et al. Should the exercise test (ET) be performed at discharge or one month later after an episode of unstable angina or non-Q-wave myocardial infarction?. Int J Card Imaging. 1991;7(1):7-14. [Medline].
Levine HD. Subendocardial infarction in retrospect: pathologic, cardiographic, and ancillary features. Circulation. Oct 1985;72(4):790-800. [Medline].
Lewis WR, Amsterdam EA, Turnipseed S, Kirk JD. Immediate exercise testing of low risk patients with known coronary artery disease presenting to the emergency department with chest pain. J Am Coll Cardiol. Jun 1999;33(7):1843-7. [Medline].
Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. Oct 19 2000;343(16):1139-47. [Medline].
Lubsen J, Tijssen JG. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT). Am J Cardiol. Jul 15 1987;60(2):18A-25A. [Medline].
Mahaffey KW, Harrington RA, Simoons ML, et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation. May 11 1999;99(18):2371-7. [Medline].
[Best Evidence] Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. Jun 15 2005;293(23):2908-17. [Medline].
[Best Evidence] Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. Jun 15 2005;293(23):2908-17. [Medline].
Moliterno D, Sapp S, Topol E. The paradoxical effect of thrombolytic therapy for unstable angina: meta-analysis. J Am Coll Cardiol. 1994;23:288A.
Moliterno D, Sgarbossa E, Armstrong P, et al. A major dichotomy in unstable angina outcome: ST depression vs. T-wave inversion--GUSTO II results. J Am Coll Cardiol. 1996;27:182A.
Moliterno DJ, Aguirre FV, Cannon CP, et al. The global unstable angina registry and treatment evaluation. Circulation. 1996;1:94.
Moliterno DJ, Asher CA, Califf RM, et al. Less myocardial but more cerebral ischemic events in African Americans than Caucasians with acute coronary syndromes: tesults from GUSTO-II. J Am Coll Cardiol. 1997;29:131A.
Moliterno DJ, Topol EJ. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. Am Heart J. Nov 2000;140(5):722-6. [Medline].
Moliterno DJ, Topol EJ. Meta-analysis of platelet GP IIb/IIIa antagonist randomized clinical trials: consistent, durable, salutary effects [abstract]. Circulation. 1997;96:I-475.
Moliterno DJ, White HD. Unstable angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS. In: Lincoff A, Topol E, eds. Contemporary Cardiology: Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Totowa,. NJ: Humana; 1999:201-27.
Nichol G, Walls R, Goldman L, et al. A critical pathway for management of patients with acute chest pain who are at low risk for myocardial ischemia: recommendations and potential impact. Ann Intern Med. Dec 1 1997;127(11):996-1005. [Medline].
Nichol G, Walls R, Goldman L, et al. A critical pathway for management of patients with acute chest pain who are at low risk for myocardial ischemia: recommendations and potential impact. Ann Intern Med. Dec 1 1997;127(11):996-1005. [Medline].
NINDS. Carotid endarterectomy for patients with asymptomatic internal carotid artery stenosis. National Institute of Neurological Disorders and Stroke. J Neurol Sci. Mar 1995;129(1):76-7. [Medline].
OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Lancet. Feb 6 1999;353(9151):429-38. [Medline].
Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med. Oct 31 1996;335(18):1333-41. [Medline].
Ondriasova E, Ondrias K, Stasko A, Nosal R, Csollei J. Comparison of the potency of five potential beta-adrenoceptor blocking drugs and eight calcium channel blockers to inhibit platelet aggregation and to perturb liposomal membranes prepared from platelet lipids. Physiol Res. 1992;41(4):267-72. [Medline].
Parker FB Jr, Neville JF Jr, Hanson EL, Webb WR. Retrograde and antegrade pressures and flows in preinfarction syndrome. Circulation. Aug 1974;50(2 Suppl):II122-6. [Medline].
Pearlman JD, Gertz ZM, Wu Y, Simons M, Post MJ. Serial motion assessment by reference tracking (SMART): application to detection of local functional impact of chronic myocardial ischemia. J Comput Assist Tomogr. Jul-Aug 2001;25(4):558-62. [Medline].
Pearlman JD, Laham RJ, Simons M. Coronary angiogenesis: detection in vivo with MR imaging sensitive to collateral neocirculation--preliminary study in pigs. Radiology. Mar 2000;214(3):801-7. [Medline].
Peterson ED. What Have We Learned from the CRUSADE Registry? Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the AHA and ACC Guidelines.www.clintrialresults.org/Slides/Crusade%20what%20have%20we%20learned.ppt. Available at www.clintrialresults.org/. Accessed Dec. 28, 2008.
Piegas LS, Flather M, Pogue J, et al. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unstable angina. Am J Cardiol. Sep 2 1999;84(5A):7M-12M. [Medline].
Pope JH, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med. Apr 20 2000;342(16):1163-70. [Medline].
Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet. May 17 1997;349(9063):1429-35. [Medline].
RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group. Lancet. Oct 6 1990;336(8719):827-30. [Medline].
Robertson RM, Wood AJ, Vaughn WK, Robertson D. Exacerbation of vasotonic angina pectoris by propranolol. Circulation. Feb 1982;65(2):281-5. [Medline].
Scirica BM, Moliterno DJ, Every NR, et al. Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry. Am Heart J. Dec 1999;138(6 Pt 1):1065-72. [Medline].
Selker HP, Beshansky JR, Griffith JL, et al. Use of the acute cardiac ischemia time-insensitive predictive instrument (ACI-TIPI) to assist with triage of patients with chest pain or other symptoms suggestive of acute cardiac ischemia. A multicenter, controlled clinical trial. Ann Intern Med. Dec 1 1998;129(11):845-55. [Medline].
Shaw LJ, Peterson ED, Kesler K, Hasselblad V, Califf RM. A metaanalysis of predischarge risk stratification after acute myocardial infarction with stress electrocardiographic, myocardial perfusion, and ventricular function imaging. Am J Cardiol. Dec 15 1996;78(12):1327-37. [Medline].
Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. JAMA. Mar 3 1999;281(9):806-10. [Medline].
Stubbs P, Collinson P, Moseley D, Greenwood T, Noble M. Prognostic significance of admission troponin T concentrations in patients with myocardial infarction. Circulation. Sep 15 1996;94(6):1291-7. [Medline].
Swahn E, Areskog M, Berglund U, Walfridsson H, Wallentin L. Predictive importance of clinical findings and a predischarge exercise test in patients with suspected unstable coronary artery disease. Am J Cardiol. Feb 1 1987;59(4):208-14. [Medline].
Tan WA, Ellis SG. Interventional cardiology. In: Marso SP, Griffin BP, Topol EJ, eds. Manual of Cardiovascular Medicine. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:722-43.
Tan WA, Moliterno DJ. Aspirin, ticlopidine, and clopidogrel in acute coronary syndromes: underused treatments could save thousands of lives. Cleve Clin J Med. Nov-Dec 1999;66(10):615-8, 621-4, 627-8. [Medline].
Tan WA, Moliterno DJ. TIMI flow and surrogate end points: what you see is not always what you get. Am Heart J. Oct 1998;136(4 Pt 1):570-3. [Medline].
Taneva E, Bogdanova V, Shtereva N. Acute coronary syndrome, comorbidity, and mortality in geriatric patients. Ann N Y Acad Sci. Jun 2004;1019:106-10. [Medline].
Tatum JL, Jesse RL, Kontos MC, et al. Comprehensive strategy for the evaluation and triage of the chest pain patient. Ann Emerg Med. Jan 1997;29(1):116-25. [Medline].
Theroux P, Lidon RM. Unstable angina: pathogenesis, diagnosis, and treatment. Curr Probl Cardiol. Mar 1993;18(3):157-231. [Medline].
Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. Oct 27 1988;319(17):1105-11. [Medline].
Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet. May 8 1999;353(9164):1547-57. [Medline].
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. Apr 7 1994;330(14):956-61. [Medline].
VAKIL RJ. PREINFARCTION SYNDROME--MANAGEMENT AND FOLLOW-UP. Am J Cardiol. Jul 1964;14:55-63. [Medline].
Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet. Jul 1 2000;356(9223):9-16. [Medline].
Wallis DE, Pope C, Littman WJ, Scanlon PJ. Safety and efficacy of esmolol for unstable angina pectoris. Am J Cardiol. Nov 15 1988;62(16):1033-7. [Medline].
Wilcox I, Freedman SB, Allman KC, et al. Prognostic significance of a predischarge exercise test in risk stratification after unstable angina pectoris. J Am Coll Cardiol. Sep 1991;18(3):677-83. [Medline].
WooD P. Acute and subacute coronary insufficiency. Br Med J. Jun 24 1961;1(5242):1779-82. [Medline].
Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable angina pectoris. N Engl J Med. Jan 13 2000;342(2):101-14. [Medline].
Further Reading
Keywords
unstable angina, myocardial infarction, acute coronary syndrome, preinfarction angina, intermediate coronary syndrome, accelerated angina, crescendo angina, chest pain, heart attack, coronary disease, hypertrophic obstructive cardiomyopathy, HOCM, microvascular disease, atherosclerotic plaque, atherosclerosis, plaque rupture, cholesterol, new-onset angina, accelerating angina, rest angina, early postinfarct angina, early postrevascularization angina, non–Q-wave myocardial infarction, non–Q-wave MI, NQMI, non-STEMI, NSTEMI, UA, MI, ACS
